Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer

Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer 585 409 Guillem Cebrian

At the end of the month of December 2019, we talked about the effectiveness of trichina as an adjuvant of cisplatin in treatment. Squamous cell carcinoma is the second most common type of skin cancer. It causes the abnormal growth of squamous cells in the epidermis and represents 20-25% of all skin cancers in Spain.

This study led by an I3PT team, led by Sílvia Gil, in close collaboration with the ALBA Synchrotron, had shown that the use of tricine as an adjuvant for chemotherapy with cisplatin increases the effectiveness of the drug against squamous cell skin carcinoma. Eventually, the studio became one article published in the open access scientific journal PLoS ONE, a publication where Dra. Gil is the first author.

In healthy individuals, squamous cells - flat cells also known as keratinocytes - continually come off to give way to new cells. However, Cumulative exposure to ultraviolet radiation can damage DNA and cause abnormal behaviors. Most often, the lesions arise in areas of the body exposed to the sun, such as the face and hands of the elderly, although it is also a common cancer in people who use tanning salons. And although this cancer is usually curable, especially if detected early, untreated lesions can grow and invade other layers of the skin and even other parts of the body. When this happens, it can become a deadly cancer.

Now, we have seen that the use of tricine as an adjuvant can increase the effectiveness of treatment and decrease its toxicity. In addition, this would be an affordable treatment that combines two existing commercial drugs ", explains Gil.

The experiments were carried out a couple of years ago when Sílvia Gil, principal investigator of the neurooncology group at I3PT, was doing a 6-month postdoctoral stay at ALBA working together with Christina Kamma-Lorger i Eduardo Solano, as well as with the scientists of the MISTRAL light line Javier Conesa i Ana J. Pérez.

MISTRAL is a line of light from the ALBA Synchrotron dedicated to the X-ray transmission microscopy which allows a 3D view of the cells in their natural state. The results of these images have shown changes in cell structure leading to cell death or apoptosis. They also analyzed the penetration of the treatment across cell membranes, which can only be observed at the nanometric scales provided by MISTRAL.

Gil, S., Solano, E., Martínez-Trucharte, F., Martínez-Esaín, J., Pérez-Berná, AJ, Conesa, JJ, Kamma-Lorger, C., Alsina, M., & Sabés, M . (2020). Multiparametric analysis of the effectiveness of cisplatin on cutaneous squamous carcinoma cells using two different types of adjuvants. PloS one15(3), and 0230022. https://doi.org/10.1371/journal.pone.0230022

Guillem Cebrian

Graduate in Information and Documentation (UB) and Master in Management and Direction of Libraries and Information Services (UB). At I3PT I am in charge of the Knowledge Management Unit and I am in charge of collecting and disseminating its scientific production. I am passionate about new technologies, data management and open science.

All entries by: Guillem Cebrian

Leave a comment

Your email address will not be published.

Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.